Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Neoleukin Therapeutics Inc (NLTX)
Neoleukin Therapeutics Inc (NLTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Neoleukin Therapeutics Inc 188 EAST BLAINE STREET SUITE 450 SEATTLE WA 98102 USA

www.neoleukin.com P: 866-245-0312

Description:

Neoleukin Therapeutics Inc. is a biopharmaceutical company. It is engaged in creating next generation immunotherapies using de novo protein design technology. The company's product candidate consists of NL-201 which is in clinical stage. Neoleukin Therapeutics Inc., formerly known as Aquinox Pharmaceuticals Inc., is based in Seattle, United States.

Key Statistics

Overview:

Market Capitalization, $K 32,799
Enterprise Value, $K -5,091
Shares Outstanding, K 9,398
Annual Sales, $ 0 K
Annual Net Income, $ -57,560 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,530 K
EBIT, $ -38,030 K
EBITDA, $ -35,910 K
60-Month Beta 1.11
% of Insider Shareholders 1.58%
% of Institutional Shareholders 52.37%
Float, K 9,249
% Float 98.42%
Short Volume Ratio 0.27

Growth:

1-Year Return 60.31%
3-Year Return -95.21%
5-Year Return -66.28%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 51.40%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.41 on 11/14/23
Latest Earnings Date 11/13/23
Earnings Per Share ttm -2.81
EPS Growth vs. Prev Qtr -105.00%
EPS Growth vs. Prev Year 65.83%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 12/19/23

NLTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -37.22%
Return-on-Assets % -30.90%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.41
Book Value/Share 8.55
Interest Coverage -2.20
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar